Aurélia Poujois, Michaela
Pernon, Jean-Marc Trocello and France
Woimant. Dystonic Dysarthria in Wilson
Disease: Efficacy of Zolpidem. Front.
Neurol., 31 October 2017 https://doi.org/10.3389/fneur.2017.00559
Wilson disease (WD) is a rare genetic disorder characterized
by copper overload in the liver and the brain. Neurological presentations are
mainly related to the accumulation of copper in the basal ganglia, the
brainstem, and the cerebellum. Dysarthria is a frequent symptom, with dystonic,
spastic, or parkinsonian components and is usually resistant to medical or
voice rehabilitation therapies. Here, we report the case of a patient with WD
diagnosed at the age of 12, who presented a severe and constant dysarthria from
dystonic origin which was unresponsive to benzodiazepines and anticholinergic
drugs. When she was 25-year-old, she tried zolpidem at bedtime for sleeping
difficulties and reported a paradoxical effect of this drug on her voice. To
confirm the effect of zolpidem on her dystonic dysarthria, we realized a full
evaluation of her dysarthria at baseline without zolpidem and after 4 days of
treatment by 10 mg twice a day. Lexical access was evaluated by the semantic
fluency; dysarthria by the Intelligibility Score, the spontaneous speech and
reading rates, the maximum phonation time on the sustained vowel [a] and by a
perceptive evaluation. Two hours after the intake of zolpidem, improvement of
all the parameters tested, with the exception of the maximum phonation time,
was observed. Semantic fluency increased by 59%, the spontaneous speech rate by
88% and the reading rate by 76%. General dystonia remained unchanged and the
tolerance of zolpidem was satisfactory. Since then, the patient takes zolpidem
5 mg five times a day, and 4 years later shows persistent improvement in oral
communication and a good drug tolerance. In this single-case study, we showed
that regular daytime intake of zolpidem could have a persisting effect on a
complex dystonic dysarthria that was resistant to usual medical treatments.
No comments:
Post a Comment